RA0411

antibody from Oursmab

Targeting: IL9 HP40, IL-9, P40

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0411

Provider

Oursmab

Product name

Enokizumab (Biosimilar Reference Antibody) (IL9)

Antibody type

Monoclonal

Description

Enokizumab is an investigational, humanized monoclonal antibody developed for the treatment of moderate-to-severe plaque psoriasis and potentially other autoimmune diseases. It belongs to the class of targeted biologic therapies that inhibit specific pro-inflammatory cytokines. Enokizumab functions as a precision interleukin inhibitor, designed to bind and neutralize its target cytokine with high specificity in the extracellular space. By blocking the interaction between this cytokine and its receptor on immune and tissue cells, enokizumab aims to interrupt a key signaling pathway that drives the chronic inflammation, keratinocyte hyperproliferation, and abnormal skin cell differentiation characteristic of psoriasis.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.